Pfizer-BioNTech vaccine effective in adolescents, companies say
The Pfizer-BioNTech COVID-19 vaccine was well tolerated and demonstrated 100% efficacy and robust antibody responses in a phase 3 clinical trial in 2,260 children aged 12-15, the vaccine’s makers announced today.
The companies plan to ask the Food and Drug Administration to expand the vaccine’s emergency use authorization to this age group based on the study data, which they said found no COVID-19 cases in the vaccinated group compared with 18 in the placebo group. The EUA currently applies to individuals age 16 and older.
The companies last week launched a trial evaluating the vaccine’s safety and efficacy in children aged 6 months to 11.
Related News Articles
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…